{"id":"NCT02090764","sponsor":"Ferrer Internacional S.A.","briefTitle":"Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo","officialTitle":"A Phase III 2 Arms, Multicenter, Randomised, Double-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2014-03-18","resultsPosted":"2016-05-19","lastUpdate":"2024-08-20"},"enrollment":412,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Impetigo"],"interventions":[{"type":"DRUG","name":"Ozenoxacin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ozenoxacin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is multicenter, randomised, placebo controlled, parallel, double blinded , superiority clinical study comparing ozenoxacin cream versus placebo, in patients with a clinical diagnosis of non-bullous or bullous impetigo.","primaryOutcome":{"measure":"Clinical Success","timeFrame":"Visit 3 (Day 6-7)","effectByArm":[{"arm":"Ozenoxacin","deltaMin":55.2,"sd":null},{"arm":"Placebo","deltaMin":39.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Puerto Rico"]},"refs":{"pmids":["30365584","29898217"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":206},"commonTop":[]}}